Rosacea Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Dermata Therapeutics, AiViva Therapeutics Galderma

Rosacea Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Dermata Therapeutics, AiViva Therapeutics Galderma
DelveInsight Business Research LLP
DelveInsight’s “Rosacea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Rosacea, historical and forecasted epidemiology, and the Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Rosacea Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Rosacea, historical and forecasted epidemiology, and the Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Rosacea Overview

Rosacea is a characteristic condition that affects the skin by causing facial erythema or redness. Around one in 10 people in the world is affected by rosacea. The symptoms of the disease manifest in various combinations and severity that often fluctuate between periods of exacerbation and remission. It is a common skin condition that causes redness and visible blood vessels in the central part of the face. It may also produce small, red, pus-filled bumps. These signs and symptoms may flare up for a period of weeks to months and then diminish for a while. Rosacea can sometimes be mistaken for acne (an allergic reaction or other skin problems). Rosacea can occur in all age groups, irrespective of gender, but most commonly affects middle-aged women who have fair skin. Many things seem to make rosacea worse but probably do not cause it in the first place. 

 

Rosacea Epidemiology Insights

  • As per the article by Mandal (n.d.), titled “Rosacea Epidemiology,” in the United States, the prevalence of rosacea seems to be on the rise. In the United Kingdom, the prevalence is 1.65 per 1000 person-years. There is a paucity of epidemiological data on rosacea, with reported prevalence rates ranging from as little as 0.09% to as much as 22.00%.

  • As per a study by Tan et al. (2013), titled “An observational cross-sectional survey of Rosacea: clinical associations and progression between subtypes,” a total of 135 subjects with rosacea were enrolled. This cross-sectional study recruited subjects with rosacea from Northern Germany. It comprised of clinical evaluation by a dermatologist and a survey of demographics and onset of rosacea-associated signs and symptoms. Rosacea was found in 87% of females and 13 % of males. Erythematotelangiectatic (ETR), papulopustular (PPR), phytates (PHY), and ocular subtypes were found in 64%, 36%, 24%, and 36% of patients. 

  • As per Reinholz et al.’s (2016) article titled “Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy,” a German registry study with a  cohort of  90,880 office employees showed a  prevalence of  2.3%.

The Report Covers the Rosacea  Epidemiology Segmented by:

  • Rosacea prevalant population 

  • Rosacea diagnosed prevalent cases 

  • Rosacea treatable prevalent  cases 

  • Rosacea subtype-specific diagnosed prevalent cases 

  • Rosacea severity specific diagnosed prevalent cases 

Rosacea Market Outlook 

The Rosacea market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Rosacea market trends by analyzing the impact of current Rosacea therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Rosacea market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Rosacea market data are presented with relevant tables and graphs to give a clear view of the market at first sight.According to DelveInsight, the Rosacea market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Rosacea Market

  • Dermata Therapeutics 

  • AiViva Therapeutics 

  • Galderma 

  • Taro Pharmaceuticals 

  • Leo Pharma 

  • Vyne Therapeutics 

And many others 

Rosacea Therapies Covered and Analyzed in the Report:

  • Azelaic acid

  • Ivermectin 

  • Doxycycline

  • AIV001

  • S5G4T-1

  • Rifaximin

And many others 

Learn more about the Key Companies and Emerging Therapies in the Rosacea Market

Table of Contents 

  1. Key Insights 

  2. Rosacea  Introduction 

  3. Executive Summary of Rosacea   

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Rosacea Emerging Therapies

  7. Rosacea Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Rosacea Market Outlook 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/